Groupe Oncologie Radiotherapie Tete Et Cou

This study tests whether adding an immunotherapy drug (pucotenlimab) to a targeted therapy (MRG003) before standard chemoradiation can shrink tumors more effectively in people with advanced head and neck cancer. About 106 adults aged 18-75 will take part. Half will get the drug c…

This phase 3 trial tests two new drug combinations (ivonescimab alone or with ligufalimab) against the standard drug pembrolizumab for people with advanced head and neck cancer that has come back or spread. About 780 adults with PD-L1-positive cancer will take part. The goal is t…